ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22^nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.